Clinical trials: Dengue Virus Infection
Dengue Fever
Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore
The purpose of this study is to assess the post-vaccination neutralizing antibody response against each dengue serotype by vaccine group.
- Trial name
- NCT02425098
- Testing
- Takeda's Tetravalent Dengue Vaccine Candidate (TDV), Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
- Where
- 3 sites in Singapore
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Takeda
Viral Haemorrhagic Fever, Dengue Fever
Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms
To meet eligibility criteria, this study and informed consent of the syndrome of fever associated with bleeding of infectious diseases, severe patients to carry out multicenter, practical randomized controlled clinical research…
- Trial name
- NCT01973855
- Testing
- Western Medicine, TCM and Western Medicine
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Guangzhou 8th People's Hospital
Dengue, Chikungunya
Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa
The differential and systematic diagnosis of malaria, dengue and chikungunya in patients with fever (≥38.5°C) of undetermined etiology would allow the identification of infection by these pathogens and thus limit the…
- Conditions
- Dengue, Chikungunya, Malaria
- Trial name
- NCT06257810
- Testing
- VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG, Standard of care practices
- Where
- 3 sites in Burkina Faso, Côte d’Ivoire
- Volunteers
- 804 people
- Sponsor
- BioMérieux
Dengue
Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
The purpose of this study is to evaluate the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 (TetraVax-DV T005) in healthy adults, adolescents, and children in Dhaka…
- Trial name
- NCT02678455
- Testing
- TV005 vaccine
- Where
- Bangladesh
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tick-Borne Encephalitis
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
Tick-borne encephalitis (TBE) is a viral illness common in the Northern Hemisphere, especially Europe and Asia. TBE infection may lead to central nervous system problems and death.
- Trial name
- NCT00118924
- Testing
- LGT(TP21)/DEN4
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever, Fever
Study of Febrile Illness for Dengue-Endemic Areas in Latin America
The purpose of this study is to detect acute febrile episodes and dengue infection in five Latin American countries to assess dengue seroprevalence.
- Trial name
- NCT01293331
- Where
- 18 sites in Brazil, Colombia and 2 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue
Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
The purpose of this research study is to test a weakened form of an experimental dengue virus challenge at different doses to test if participants develop symptoms or circulating virus in the blood (called viremia).
- Trial name
- NCT05268302
- Testing
- Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Dengue, Dengue Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
The aim of this study is to evaluate the immunogenicity and safety of the CYD dengue vaccine in India adult subjects. Primary Objectives: To describe the neutralizing antibody response to each dengue virus serotype before the…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01550289
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
- Where
- 5 sites in India
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection
The study will collect the blood samples from 350 healthy persons and 350 persons infected with dengue fever.
- Trial name
- NCT00688389
- Testing
- case/control
- Where
- Taiwan
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Dengue
Clinical Trial of Diagnostic Tests and Clinical Algorithms for Dengue in Febrile Subjects in Endemic Areas in Colombia
The present study aimed to develop a sensitive dengue diagnostic clinical algorithm using the resources that are available at the health care institutions, clinical expertise, and identification of signs and symptoms and…
- Trial name
- NCT04063774
- Testing
- Dengue calculator
- Where
- 3 sites in Colombia
- Volunteers
- 1,045 people
- Sponsor
- Lyda Osorio
Arbovirus Infections
Spatial Repellents for Arbovirus Control
Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly.
- Trial name
- NCT03553277
- Testing
- transfluthrin
- Where
- Peru
- Volunteers
- 18,240 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Dengue Fever
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06579755
- Testing
- TDV
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
Dengue viruses are mosquito-borne flaviviruses. Each year, dengue viruses infect millions of people throughout the tropics and subtropics.
- Trial name
- NCT02450838
- Testing
- V180, Alhydrogel™
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
The purpose of this study was to demonstrate that different CYD dengue vaccine lots manufactured using the same method and in the same location but at different times produce an equivalent immunological response after 3 doses.
- Trial name
- NCT01134263
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- Where
- 8 sites in Australia
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Arbovirus Infections
The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers
International travel has increased dramatically in recent years. Vector-borne pathologies such as malaria and arboviruses are common etiologies of post-travel fever, which are prevalent in similar geographical areas (tropical and…
- Trial name
- NCT06651372
- Testing
- The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Acquired Bleeding Disorder, Dengue Haemorrhagic Fever
Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
This trial is conducted in Asia. The aim of this is to investigate the efficacy and safety of activated recombinant human factor VII (rFVIIa) in achieving haemostasis in patients with Dengue haemorrhagic fever (DHF).
- Trial name
- NCT01601613
- Testing
- activated recombinant human factor VII
- Where
- 9 sites in Malaysia, Philippines and 1 more
- Volunteers
- 28 people
- Sponsor
- Novo Nordisk A/S
Dengue Fever
Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome
Dengue is an arthropod-borne disease, found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas. Unfortunately, there is no intervention available to stop dengue severity.
- Trial name
- NCT06071481
- Testing
- Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution
- Where
- Bangladesh
- Volunteers
- 120 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Dengue
Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine
Infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries, and the development of a dengue vaccine is a top health priority.
- Trial name
- NCT02684383
- Testing
- rDEN3∆30
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
Background: Some mosquitos carry viruses that can cause disease. Some examples are dengue and Zika. The mosquitos spread disease by biting people and infecting them with the virus.
- Trial name
- NCT03534245
- Where
- Cambodia
- Volunteers
- 775 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
The purpose of this study is to assess the safety of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) (previously DENVax) in healthy adults when given as either a subcutaneous (SC) or intradermal (ID) injection at two dose…
- Trial name
- NCT01224639
- Testing
- TDV - Low Dose, TDV - High Dose
- Where
- Colombia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Inviragen Inc.